Research Topics
Genomes and Genes | Jose A Martinez-ClimentSummaryAffiliation: University of Navarra Country: Spain Publications
| Collaborators
|
Detail Information
Publications
Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancerJoan Climent
Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, and Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Spain
Cancer Res 67:818-26. 2007..However, these initial findings should be evaluated in randomized clinical trials...
Lymphoma stem cells: enough evidence to support their existence?Jose A Martinez-Climent
Division of Oncology, Center for Applied Medical Research, University of Navarra, Avda Pio XII, 55 31008 Pamplona, Spain
Haematologica 95:293-302. 2010....- Somatic stem cells and the origin of cancerJose A Martinez-Climent
Division of Oncology, Center for Applied Medical Research University of Navarra, Pamplona, Spain
Clin Transl Oncol 8:647-63. 2006.... - Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomasCinta Mestre-Escorihuela
Center for Applied Medical Research CIMA, University of Navarra, Avda Pio XII, 55, Pamplona 31008, Spain
Blood 109:271-80. 2007..Our microarray strategy has identified novel candidate tumor suppressor genes inactivated by genetic and epigenetic mechanisms that substantially vary among the B-NHL subtypes... - Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterationsJose A Martinez-Climent
Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Spain
Blood 101:3109-17. 2003..This process is associated with the acquisition of a variable spectrum of genomic imbalances affecting recurrent chromosomal areas that harbor overexpressed or underexpressed genes targeted upon transformation... 
Integrative oncogenomic analysis of microarray data in hematologic malignanciesJose A Martinez-Climent
Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
Methods Mol Biol 576:231-77. 2010..We also present the basic aspects of these methodologies and their present and future application in clinical oncology...- Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphomaJose A Martinez-Climent
Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Avda Blasco Ibanez, 17 46010 Valencia, Spain
Leuk Lymphoma 44:459-64. 2003..We hypothesize that the trisomy of 3q may correlate with the indolent nature of SMZL, and that the loss of this acquired abnormality leads to or accompanies the development of blastic tumors... - Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphomaJose A Richter-Larrea
Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
Blood 116:2531-42. 2010..We suggest that the combination of histone-deacetylase inhibitors and high-dose chemotherapy may overcome chemoresistance, achieve durable remission, and improve survival of patients with BL... - Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genesFanny Rubio-Moscardo
Center for Applied Medical Research CIMA, Division of Oncology, University of Navarra, Avda Pio XII, 55, Pamplona 31008, Spain
Blood 106:3214-22. 2005..Our data suggest that TRAIL-R1 and TRAIL-R2 act as dosage-dependent tumor suppressor genes whose monoallelic deletion can impair TRAIL-induced apoptosis in B-cell lymphoma... - Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcomeFanny Rubio-Moscardo
Department of Hematology and Medical Oncology, , University of Valencia, Spain
Blood 105:4445-54. 2005..3 to 15.7). Our study highlights the genomic profile as a predictor for clinical outcome and suggests that "genome scanning" of chromosomes 1p21, 9q21-q22, 9p21.3-P16/INK4a, and 17p13.1-TP53 may be clinically useful in MCL... - Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemiaEdurne San Jose-Eneriz
Hematology Department and Area of Cell Therapy, Clinica Universitaria, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain
Eur J Cancer 45:1877-89. 2009..However, the mechanisms involved in the regulation of BIM in CML and its role in the clinical setting have not been established... - Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancerJoan Climent
Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Valencia, Spain 46010
Clin Cancer Res 8:3863-9. 2002..Furthermore, the genomic loss of 18p may identify a poor prognostic subgroup of patients with HRBC... - A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphomaElena Beltran
Center for Applied Medical Research, University of Navarra, Pamplona, Spain
Proc Natl Acad Sci U S A 108:12461-6. 2011..This effective combination therapy also might be exploited in other cyclin-D1-expressing tumors... - LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcomeRaquel Malumbres
Division of Oncology, Center for Applied Medical Research CIMA University of Navarra, Pamplona, Spain
Haematologica 96:980-6. 2011..The implication of LMO2 in B-cell acute lymphoblastic leukemia must still be explored...